Sir Andrew Witty to retire in March 2017, GSK confirms

17 March 2016

The chief executive of UK pharma major GlaxoSmithKline (LSE: GSK), Sir Andrew Witty, will retire in March next year, the company announced on Thursday.

Along with presenting its 2015 Annual Report, GSK told shareholders that he had indicated to the board his intention to retire in a year’s time, and his last day will be March 31, 2017.

This confirms rumors which had been circulating in recent months that 52-years old Sir Andrew was planning to step down. GSK will now start searching for his successor. Internal and external candidates will be considered.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK